Skip to content
DataLookout
Menu

NCT02226276

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

StatusActive, Not Recruiting
PhaseNot applicable
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 23 versions: 18 with changes below, 5 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Start date: Jan 7, 2015 to Feb 25, 2015
    • Eligibility criteria expanded, about 14 words
    • Study completion pushed from Sep 29, 2026 to Sep 7, 2027
  2. Minor Study completion date: Oct 30, 2025 to Sep 29, 2026v22
  3. Minor Study completion date: Dec 7, 2024 to Oct 30, 2025v21
  4. Minor Study completion date: Dec 30, 2023 to Dec 7, 2024v20
  5. Minor Study completion date: May 30, 2023 to Dec 30, 2023v19
Show 12 earlier versionsHide 12 earlier versions
  1. Minor Trial status: Completed to Active, Not Recruiting
    • Study completion date: Dec 7, 2021 to May 30, 2023
    v18
  2. Notable Results first posted: Jul 20, 2022
    • Primary endpoints: 4 to 2
    • Trial status: Active, Not Recruiting to Completed
    v17
  3. Notable Primary and study completion dates: Dec 2020 to Dec 7, 2021v16
  4. Notable Primary and study completion dates: May 2020 to Dec 2020v15
  5. Notable Primary and study completion dates: Feb 2019 to May 2020v14
  6. Notable Primary and study completion dates: May 2018 to Feb 2019v12
  7. Minor Study description expanded, about 3 wordsv11
  8. Notable Primary completion date: May 2017 to May 2018v9 Show 4 more changesShow less
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: May 2018
    • Start date: Jan 2015 to Jan 7, 2015
    • Site details revised
  9. Notable Eligibility criteria expanded, about 14 words
    • Primary completion date: Dec 2016 to May 2017
    v8
  10. Notable Eligibility criteria shortened, about 9 wordsv7
  11. Notable Eligibility criteria expanded, about 41 words
    • Study description revised
    v3
  12. Notable Trial status: Not Yet Recruiting to Recruiting
    • Start date: Dec 2014 to Jan 2015
    • Site details revised
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Relationship Between Average Tumor Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response
Timeframe: Baseline
Relationship Between Tumor Minimum Uptake of Copper Cu 64-DOTA-trastuzumab as Measured by PET and Patient Best Response
Timeframe: Up to 1 year

Arms and interventions

Diagnostic (copper Cu 64-DOTA-trastuzumab PET)Experimental

Patients undergo whole body fludeoxyglucose F 18 PET/CT. Patients then receive trastuzumab IV over 15 minutes immediately before receiving copper Cu 64-DOTA-trastuzumab IV and then undergo PET scans at 24 and 48 hours. Patients then receive ado-trastuzumab emtansine IV every 3 weeks until complete response or disease progression at the discretion of the treating oncologist. Patients undergo restaging by whole body fludeoxyglucose F 18 PET/CT every 6 weeks after initiation of treatment until disease progression.

Radiation: fludeoxyglucose F 18, copper Cu 64-DOTA-trastuzumab

Procedures: positron emission tomography, computed tomography

Biologicals: trastuzumab, ado-trastuzumab emtansine

Other: laboratory biomarker analysis

Sites

1 site in 1 country

  • City of Hope Medical CenterDuarte, California, United States